Abstract
Relapsed/refractory multiple myeloma (MM) is always a challenge in the field of MM treatment.In the 19th European Hematology Association (EHA) annual congress,there was a detailed and full-length description on the definition,prognosis,therapeutic strategies and new drugs of the relapsed/refractory MM.New agents with activity and good tolerability are promising in the future. Key words: Multiple myeloma; Relapsed; Refractory; Treatment; European Hematology Association annual congress
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
